{"task_id": "492f67a056c8a452", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 212/464)", "text": "e 5 HIAA (sens 73%, spc 100%)\nCarcinoid Tumors\n201\n\n--- Page 223 ---\nINVESTIGATIONS (CONT\u2019D)\n\u0002\nIMAGING\nCT\nchest/abd/pelvis,\nsomatostatin\nscintigraphy (sens 89%), MIBG scan (useful if\nsomatostatin scan negative). Echocardiogram\n\u0002\nBIOPSY\nensure\npathology\nincludes\nKi67\nimmunohistochemistry\nSPECIAL\n\u0002\nPANCREATIC NEUROENDOCRINE TUMOR WORKUP\npan\ncreatic polypeptide, a hCG, chromogranin A, gas\ntrin,somatostatin,serumVIP,glucagon,insulinlevels\n\u0002\nSERUM SEROTONIN\nwhen urinary 5 HIAA equivocal\n\u0002\nEPINEPHRINE\nOR\nPENTAGASTRINE\nPROVOCATION\nTESTS\nif flushing and normal markers\nMANAGEMENT\nSYMPTOM CONTROL (AVOID PRECIPITATING\nFACTORS)\n\u0002\nDIARRHEA\noctreotide 100 600 mg SC div 2 4 doses,\noctreotide depot 10 30 mg IM every 28 days, lanreo\ntide, loperamide 4 mg \u00031 dose, then 2 mg q4h PRN,\nmaximum 16 mg/day, atropine diphenoxylate 1 2\ntabs q6 8h, cyproheptadine, methysergide, ondan\nsetron 8 mg PO TID. Gastric carcinoid can respond to\na histamine blocker\n\u0002\nHYPOTENSION\npure\na adrenergic\nmedications\nsuch as methoxamine and angiotensin. Corticos\nteroids may be useful for prophylaxis. Strictly avoid\nb adrenergic agonists such as epinephrine and\ndopamine as they may aggravate hypotension\n\u0002\nFLUSHING\noctreotide, prochlorperazine 10 mg PO\nQID (foregut), phenoxybenzamine 10 20 mg PO\nBID, prednisone 20 40 mg PO daily (foregut)\n\u0002\nBRONCHOSPASM\nsalbutamol 2 puffs INH q4h PRN,\nipratropium, theophylline\n\u0002\nCARCINOID HEART DISEASE\nmedical management of\nheart failure, valvular replacement may be considered\nbut patients are usually high risk surgical candidates\nLOCALIZED DISEASE\nresection\nADVANCED/METASTATIC DISEASE\n\u0002\nPALLIATIVE RESECTION\nfor debulking, prevention of\nmesenteric fibrosis by mid gut carcinoids, and\ntreatment of obstruction and extraintestinal pri\nmary tumors such as bronchial and ovarian\nMANAGEMENT (CONT\u2019D)\ncarcinoids that rarely cause carcinoid syndrome\nwithout hepatic metastasis\n\u0002\nCHEMOTHERAPY\nlimited activity, streptozocin/5\nfluorouracil or doxorubicin, interferon a (now\nrarely used). Consider temozolomide, cisplatin,\nand etoposide for patients with poorly differen\ntiated tumors\n\u0002\nTARGET RADIOTHERAPY WITH RADIOLABELED SOMATOS-\nTATIN ANALOGUES\ndifficult to access as only few\ninstitutions offer this therapy\n\u0002\nHEPATIC\nMETASTASES\nresection,\nradiofrequency\nablation and cryoablation, hepatic artery embo\nlization\nTREATMENT ISSUES\nSOMATOSTATIN ANALOGUES\noctreotide is a long\nacting somatostatin analogue that binds to somatos\ntatin receptor 2 and to a certain extent receptors 3 and\n5 and inhibits secretion of various hormones\n\u0002\nINDICATIONS\nsymptomatic with hormone induced\nsyndromes. Can be used in asymptomatic patients\nto delay progression for midgut tumors, and perio\nperatively to prevent carcinoid crisis. Controversial\nindications include post surgery, post embolization\nor radiofrequency ablation, and post adjuvant treat\nment with no evidence of disease\n\u0002\nDOSING\ngive 50 mg as test dose (may cause gas\ntric atony and skin toxicity), then 100 150 mg SC\nBID TID. May double dose every 3 4 days until\nsymptom free. Once on a stable dose, may switch\nto long acting formulation (200 600 mg/day !\n20 mg/month or 750 1500 mg/day ! 30 mg/\nmonth). Continue life long\n\u0002\nADVERSE EFFECTS\nnausea, gastric atony, abdom\ninal\ncramps,\ndiarrhea/constipation,\ngallstones,\nimpaired glucose tolerance, hypothyroidism, dys\npnea, arrhythmia, HTN, fatigue, headache, dizzi\nness, fever, flu like symptoms\nFOLLOW UP\nclinical assessment along with chro\nmogranin A and 24 h urine 5 HIAA every 3 6 months,\nroutine imaging every 6 12 months\nGastrointestinal Stromal Tumor\nPATHOPHYSIOLOGY\nHISTOLOGY\nspindle cell or epithelioid tumor that\nmay be derived from interstitial cells of Cajal (pace\nmaker cells involved in peristalsis)\nLOCATIONS\nstomach (50%), small intestine (25%),\ncolon (10%), esophagus, rectum, mesentery, and\nretroperitoneum\nMOLECULAR BIOLOGY\ncharacteristic c kit/CD117\n(90%) and/or PDGFRa mutation, CD34+ (66%)\nNATURAL HISTORY\nclinical behavior of GIST is\nvariable and the risk of recurrence and metastases\ndepends on various adverse prognostic factors.\nMetastases most commonly involve liver, rarely regio\nnal lymph nodes and almost never lungs\nPATHOPHYSIOLOGY (CONT\u2019D)\n202\nGastrointestinal Stromal Tumor", "text_length": 4207, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 212/464)", "type": "chunk", "chunk_index": 211, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.538210", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.538954", "status": "complete", "chunks_added": 3}